Arch Dermatol Res
Archives of Dermatological Research
0340-3696
1432-069X
Springer-Verlag
Berlin/Heidelberg


1800369
17221215
726
10.1007/s00403-006-0726-5
Review Article


Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies

Utikal
Jochen

1

Schadendorf
Dirk

1
2

Ugurel
Selma

+49-621-3833905
+49-621-3832163
s.ugurel@dkfz.de

1
2

1
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg,  Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany 
2
Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany 

13
1
2007

3
2007

298
10
469
477
3
11
2006

6
12
2006

6
12
2006


© Springer-Verlag 2006

Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.

Keywords
Skin cancer
Biomarker
Prognosis
Serum
Immunohistochemistry

issue-copyright-statement
© Springer-Verlag 2007




Introduction
Biomarkers play an important role in the diagnosis and prognostic classification of various cancer entities and can moreover be useful in monitoring the patient’s clinical course of disease and response to therapy. In general, biomarkers are proteins, less often carbohydrates or lipids, and their expression profiles are associated with malignant disease. In the majority of cases, the marker molecules are expressed by the tumour cells themselves or by cells of the tumour microenvironment. Thus, most biomarkers can primarily be found in malignant tissues, but after active secretion or passive release at tumour cell destruction also become detectable in body fluids like blood, lymph or urine.
Besides morphological and histopathological biomarkers (anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression, as well as proteomic profiling data, indicates new candidate molecules involved in skin cancer pathogenesis, which may after further validation represent new markers superior to existing ones. This ongoing process of biomarker identification and validation would result in a rapidly changing molecular view and classification of skin cancers.

Malignant melanoma
Serologic markers of malignant melanoma
1
1
Table 1
Serologic markers of malignant melanoma


Serologic marker
Selected literature


Melanocyte lineage/differentiation antigens
S100-beta
30
71
32
33
18
43
28
]

MIA (melanoma inhibitory activity)
9
8
10
74
28
]

Tyrosinase
2
]

5-S-Cysteinyldopa
91
34
]

L-Dopa/L-tyrosine
75
]

Proangiogenic factors
VEGF (vascular endothelial growth factor)
83
56
12
]

BFGF (basic fibroblast growth factor)
83
12
]

IL-8 (Interleukin-8)
68
83
12
]

Molecules involved in cell adhesion and motility
sICAM-1 (soluble intracellular adhesion molecule 1)
34
87
94
]

sVCAM (soluble vascular cell adhesion molecule 1)
26
87
]

Matrix metalloproteinases (MMP)-1 and 9
63
53
]

Cytokines and cytokine receptors
IL-6 (Interleukin-6)
50
73
]

IL-10 (Interleukin-10)
21
51
]

sIL-2R (soluble interleukin-2-receptor)
11
58
]

HLA molecules
sHLA-DR (soluble HLA-DR)
62
]

sHLA-class-I (soluble HLA-class I)
89
]

Others
LDH (lactate dehydrogenase)
72
18
6
]

CRP (C-reactive protein) 
19
]

Albumin
72
]

TuM2-PK (Tumour pyruvate kinase type M2)
81
]

sFas/CD95 
84
]

YKL-40
69
70
]

CYT-MAA (cytoplasmic melanoma-associated antigen)
85
]

HMW-MAA (high-molecular-weight melanoma-associated antigen)
85
]




Fig. 1
MIA
)




49
59
30
9
8
].
18
43
36
2
71
33
74
32
1
Fig. 2
P
 = 0.003 by log rank test; detection system LIAISON Sangtec 100)




18
6
]. It, moreover, serves as a stratification parameter in most randomized therapy trials performed in stage-IV melanoma and may also be used to monitor therapy response in these patients.
1
1
). However, neither one of these markers could be confirmed to be superior to S100-beta or LDH in reflecting the prognosis of patients in advanced disease stages, nor could any marker be shown to be of strong prognostic relevance in early stage tumour-free patients.
46
].

Immunohistochemical markers of malignant melanoma
Cutaneous malignant melanoma regularly develops from the radial to the vertical growth phase and thereafter to metastatic disease. The variability of this clinical course is only partially explained by morphological and histopathological parameters like primary tumour localization, patient gender and age, mitotic rate, tumour thickness and ulceration. There is a need to identify molecular variables, which help to assign patients to specific risk groups. The number of modalities for diagnosing and subclassifying malignant melanomas is rapidly increasing and includes immunohistochemistry of tissue sections and microarrays, gene expression profiling, comparative genomic hybridization and mutational analysis. These methodologies promise to improve our prognostic classification systems, as well as our diagnostic and therapeutic potential.
44
2
Table 2
Immunohistochemical markers of malignant melanoma associated with prognosis


Association with poor prognosis
Selected literature


Melanocyte lineage/Differentiation antigens

 gp100/HMB45
Increased expression
52
]

Tumour suppressors/oncogenes/signal transducers

INK4A

Decreased expression
47
3
]

 PTEN
Decreased expression
48
]

 pRb (retinoblastoma protein)
Inactivation due to protein phosphorylation
65
]

 EGFR (epidermal growth factor receptor)
Increased expression
80
]

 p-Akt (activated serine-threonine protein kinase B)
Increased expression
17
]

 c-Kit
Expression
35
82
]

 c-myc
Increased expression
42
]

 AP-2 (activator protein-2alpha) transcription factor
Loss of nuclear AP-2 expression
7
]

 HDM2 (human homologue of murine mdm2)
Increased expression
61
]

bcl-6
Expression
3
]

Cell cycle associated proteins

 Ki67 (detected by Mib1)
Increased expression
29
3
57
]

 Cyclin A, B, D, E
Increased expression
24
25
]

CIP1

Decreased expression
3
]

 Geminin
Increased expression
92
]

 PCNA (proliferating cell nuclear antigen)
Increased expression
92
]

Regulators of apoptosis

 bcl-2
Increased expression
78
]

 bax 
Decreased expression
23
]

 Bak
Decreased expression
23
]

 APAF-1 (Apoptotic protease activating factor-1)
Decreased expression
27
]

 Surviving
Increased expression
78
]

Molecules involved in angiogenesis

 LYVE-1 (lymphatic vascular endothelial hyaluronan receptor-1) 
Increased expression
16
]

 PTN (pleiotrophin)
Increased expression
93
]

Molecules involved in cell adhesion and motility

 P-Cadherin
Strong cytoplasmic expression
5
]

 E-Cadherin
Decreased expression
4
]

 Beta-catenin
Loss of nuclear staining
5
]

 Integrins beta1 and beta3 
Increased expression
66
]

 MMPs (matrix metalloproteinases)
Increased expression
63
]

 Dysadherin
Increased expression
54
]

 CEACAM1 (carcinoembryonic-antigen-related cell-adhesion molecule 1)
Increased expression
79
]

 Osteonectin (also termed BM40 or SPARC (secreted protein, acidic and rich in cysteine))
Increased expression
45
]

Others 

 TA (telomerase activity) 
Increased expression
13
]

 Melastatin
Decreased expression
22
]

 ALCAM/CD166 (Activated leukocyte cell adhesion molecule)
Increased expression
77
]

 CXCR4 receptor
Increased expression
67
]

 Metallothionein
Increased expression
88
]





92
92
] recommend the use of a battery of antibodies that may improve the future determination of prognosis and treatment stratification. The determination of karyopherin-alpha2, MCMs (minichromosome maintenance proteins), geminin and PCNA over-expression could be used for screening in melanoma patients with a poor clinical outcome.


Squamous cell carcinoma of the skin
60
].
76
].
41
41
76
].
37
38
64
64
55
].

Cutaneous T-cell lymphomas
90
].
20
40
39
].
86
86
31
].

Conclusion and future directions
14
15
]. It may be expected that the rapidly increasing knowledge of molecular mechanisms would lead to mainly biomarker-based, rather than morphology-based, classification systems that might facilitate an individualized, molecular-driven cancer therapy.


This work was supported by a grant from the German Cancer Aid/Deutsche Krebshilfe (Proposal No. 106856).

References
1.
Acland
K

Evans
AV

Abraha
H

Healy
CM

Roblin
P

Calonje
E

Orchard
G

Higgins
E

Sherwood
R

Russell-Jones
R


Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma
Br J Dermatol
2002
146
832
835
10.1046/j.1365-2133.2002.04691.x

12000380


2.
Agrup
P

Carstam
R

Wittbjer
A

Rorsman
H

Rosengren
E


Tyrosinase activity in serum from patients with malignant melanoma
Acta Derm Venereol
1989
69
120
124

2564228


3.
Alonso
SR

Ortiz
P

Pollan
M

Perez-Gomez
B

Sanchez
L

Acuna
MJ

Pajares
R

Martinez-Tello
FJ

Hortelano
CM

Piris
MA



Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study
Am J Pathol
2004
164
193
203

14695333


4.
Andersen
K

Nesland
JM

Holm
R

Florenes
VA

Fodstad
O

Maelandsmo
GM


Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
Mod Pathol
2004
17
990
997
10.1038/modpathol.3800151

15133476


5.
Bachmann
IM

Straume
O

Puntervoll
HE

Kalvenes
MB

Akslen
LA


Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma
Clin Cancer Res
2005
11
8606
8614
10.1158/1078-0432.CCR-05-0011

16361544


6.
Balch
CM

Buzaid
AC

Soong
SJ

Atkins
MB

Cascinelli
N

Coit
DG

Fleming
ID

Gershenwald
JE

Houghton
A

Kirkwood
JM



Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
J Clin Oncol
2001
19
3635
3648

11504745


7.
Berger
AJ

Davis
DW

Tellez
C

Prieto
VG

Gershenwald
JE

Johnson
MM

Rimm
DL

Bar-Eli
M


Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction
Cancer Res
2005
65
11185
11192
10.1158/0008-5472.CAN-05-2300

16322269


8.
Blesch
A

Bosserhoff
AK

Apfel
R

Behl
C

Hessdoerfer
B

Schmitt
A

Jachimczak
P

Lottspeich
F

Buettner
R

Bogdahn
U


Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA
Cancer Res
1994
54
5695
5701

7923218


9.
Bogdahn
U

Apfel
R

Hahn
M

Gerlach
M

Behl
C

Hoppe
J

Martin
R


Autocrine tumor cell growth-inhibiting activities from human malignant melanoma
Cancer Res
1989
49
5358
5363

2766302


10.
Bosserhoff
AK

Kaufmann
M

Kaluza
B

Bartke
I

Zirngibl
H

Hein
R

Stolz
W

Buettner
R


Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma
Cancer Res
1997
57
3149
3153

9242442


11.
Boyano
MD

Garcia-Vazquez
MD

Lopez-Michelena
T

Gardeazabal
J

Bilbao
J

Canavate
ML

Galdeano
AG

Izu
R

Diaz-Ramon
L

Raton
JA



Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma
Br J Cancer
2000
83
847
852
10.1054/bjoc.2000.1402

10970683


12.
Brennecke
S

Deichmann
M

Naeher
H

Kurzen
H


Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma
Melanoma Res
2005
15
515
522
10.1097/00008390-200512000-00006

16314737


13.
Carvalho
L

Lipay
M

Belfort
F

Santos
I

Andrade
J

Haddad
A

Brunstein
F

Ferreira
L


Telomerase activity in prognostic histopathologic features of melanoma
J Plast Reconstr Aesthet Surg
2006
59
961
968
10.1016/j.bjps.2006.01.022

16920589


14.
Curtin
JA

Busam
K

Pinkel
D

Bastian
BC


Somatic Activation of KIT in Distinct Subtypes of Melanoma
J Clin Oncol
2006
14
14

Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic Activation of KIT in Distinct Subtypes of Melanoma. J Clin Oncol 14:14 

15.
Curtin
JA

Fridlyand
J

Kageshita
T

Patel
HN

Busam
KJ

Kutzner
H

Cho
KH

Aiba
S

Brocker
EB

LeBoit
PE



Distinct sets of genetic alterations in melanoma
N Engl J Med
2005
353
2135
2147
10.1056/NEJMoa050092

16291983


16.
Dadras
SS

Paul
T

Bertoncini
J

Brown
LF

Muzikansky
A

Jackson
DG

Ellwanger
U

Garbe
C

Mihm
MC

Detmar
M


Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival
Am J Pathol
2003
162
1951
1960

12759251


17.
Dai
DL

Martinka
M

Li
G


Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases
J Clin Oncol
2005
23
1473
1482
10.1200/JCO.2005.07.168

15735123


18.
Deichmann
M

Brenner
A

Bock
M

Jäckel
A

Uhl
K

Waldmann
V

Näher
H


S100-beta, melanoma-inhibiting activity and lactate dehydrogenase discriminate progressive from non-progressive American Joint Committee on Cancer stage IV melanoma
J Clin Oncol
1999
17
1891
1896

10561230


19.
Deichmann
M

Kahle
B

Moser
K

Wacker
J

Wust
K


Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase
Br J Cancer
2004
91
699
702

15280926


20.
Dippel
E

Goerdt
S

Assaf
C

Stein
H

Orfanos
CE


Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement
Lancet
1997
350
1776
1777
10.1016/S0140-6736(05)63605-7

9413486


21.
Dummer
W

Becker
JC

Schwaaf
A

Leverkus
M

Moll
T

Brocker
EB


Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma
Melanoma Res
1995
5
67
68
10.1097/00008390-199502000-00008

7734958


22.
Duncan
LM

Deeds
J

Hunter
J

Shao
J

Holmgren
LM

Woolf
EA

Tepper
RI

Shyjan
AW


Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis
Cancer Res
1998
58
1515
1520

9537257


23.
Fecker
LF

Geilen
CC

Tchernev
G

Trefzer
U

Assaf
C

Kurbanov
BM

Schwarz
C

Daniel
PT

Eberle
J


Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis
J Invest Dermatol
2006
126
1366
1371
10.1038/sj.jid.5700192

16528364


24.
Florenes
VA

Faye
RS

Maelandsmo
GM

Nesland
JM

Holm
R


Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
Clin Cancer Res
2000
6
3614
3620

10999753


25.
Florenes
VA

Maelandsmo
GM

Faye
R

Nesland
JM

Holm
R


Cyclin a expression in superficial spreading malignant melanomas correlates with clinical outcome
J Pathol
2001
195
530
536
10.1002/path.1007

11745687


26.
Franzke
A

Probst-Kepper
M

Buer
J

Duensing
S

Hoffmann
R

Wittke
F

Volkenandt
M

Ganser
A

Atzpodien
J


Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma
Br J Cancer
1998
78
40
45

9662248


27.
Fujimoto
A

Takeuchi
H

Taback
B

Hsueh
EC

Elashoff
D

Morton
DL

Hoon
DS


Allelic imbalance of 12q22–23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma
Cancer Res
2004
64
2245
2250
10.1158/0008-5472.CAN-03-2932

15026369


28.
Garbe
C

Leiter
U

Ellwanger
U

Blaheta
HJ

Meier
F

Rassner
G

Schittek
B


Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients
Cancer
2003
97
1737
1745
10.1002/cncr.11250

12655531


29.
Gimotty
PA

Belle
P

Elder
DE

Murry
T

Montone
KT

Xu
X

Hotz
S

Raines
S

Ming
ME

Wahl
P



Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma
J Clin Oncol
2005
23
8048
8056
10.1200/JCO.2005.02.0735

16258103


30.
Guo
HB

Stoffel-Wagner
B

Bierwirth
T

Mezger
J

Klingmuller
D


Clinical significance of serum S100 in metastatic malignant melanoma
Eur J Cancer
1995
31A
924
928
10.1016/0959-8049(95)00087-9

7646923


31.
Hassel
JC

Meier
R

Joller-Jemelka
H

Burg
G

Dummer
R


Serological immunomarkers in cutaneous T cell lymphoma
Dermatology
2004
209
296
300
10.1159/000080852

15539892


32.
Hauschild
A

Engel
G

Brenner
W

Glaeser
R

Moenig
H

Henze
E

Christophers
E


Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy
Br J Dermatol
1999a
140
1065
1071
10.1046/j.1365-2133.1999.02905.x

10354072


33.
Hauschild
A

Engel
G

Brenner
W

Glaeser
R

Monig
H

Henze
E

Christophers
E


S100B protein detection in serum is a significant prognostic factor in metastatic melanoma
Oncology
1999b
56
338
344
10.1159/000011989

10343200


34.
Hirai
S

Kageshita
T

Kimura
T

Tsujisaki
M

Imai
K

Wakamatsu
K

Ito
S

Ono
T


Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression
Melanoma Res
1997
7
58
62
10.1097/00008390-199702000-00009

9067966


35.
Janku
F

Novotny
J

Julis
I

Julisova
I

Pecen
L

Tomancova
V

Kocmanova
G

Krasna
L

Krajsova
I

Stork
J



KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients
Melanoma Res
2005
15
251
256
10.1097/00008390-200508000-00004

16034302


36.
Jury
CS

McAllister
EJ

MacKie
RM


Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma
Br J Dermatol
2000
143
269
274
10.1046/j.1365-2133.2000.03650.x

10951132


37.
Keehn
CA

Smoller
BR

Morgan
MB


Ets-1 immunohistochemical expression in non-melanoma skin carcinoma
J Cutan Pathol
2004
31
8
13
10.1046/j.0303-6987.2004.0158.x

14675279


38.
Kerkela
E

Ala-aho
R

Klemi
P

Grenman
S

Shapiro
SD

Kahari
VM

Saarialho-Kere
U


Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome
J Pathol
2002
198
258
269
10.1002/path.1198

12237887


39.
Klemke
CD

Goerdt
S

Schrama
D

Becker
JC


New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas
J Dtsch Dermatol Ges
2006
4
395
406
10.1111/j.1610-0387.2006.05982.x

16686607


40.
Klemke
CD

Mansmann
U

Poenitz
N

Dippel
E

Goerdt
S


Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome
Br J Dermatol
2005
153
118
124
10.1111/j.1365-2133.2005.06676.x

16029336


41.
Koseki
S

Aoki
T

Ansai
S

Hozumi
Y

Mitsuhashi
Y

Kondo
S


An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis
J Dermatol
1999
26
416
422

10458080


42.
Kraehn
GM

Utikal
J

Udart
M

Greulich
KM

Bezold
G

Kaskel
P

Leiter
U

Peter
RU


Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
Br J Cancer
2001
84
72
79
10.1054/bjoc.2000.1535

11139316


43.
Krähn
G

Kaskel
P

Sander
S

Waizenhofer
PJ

Wortmann
S

Leiter
U

Peter
RU


S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase
Anticancer Res
2001
21
1311
1316

11396205


44.
Mangini
J

Li
N

Bhawan
J


Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness
Am J Dermatopathol
2002
24
270
281
10.1097/00000372-200206000-00016

12140448


45.
Massi
D

Franchi
A

Borgognoni
L

Reali
UM

Santucci
M


Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas
Hum Pathol
1999
30
339
344
10.1016/S0046-8177(99)90014-X

10088554


46.
Mian
S

Ugurel
S

Parkinson
E

Schlenzka
I

Dryden
I

Lancashire
L

Ball
G

Creaser
C

Rees
R

Schadendorf
D


Serum fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients
J Clin Oncol
2005
23
5088
5093
10.1200/JCO.2005.03.164

16051955


47.
Mihic-Probst
D

Mnich
CD

Oberholzer
PA

Seifert
B

Sasse
B

Moch
H

Dummer
R


p16 expression in primary malignant melanoma is associated with prognosis and lymph node status
Int J Cancer
2006
118
2262
2268
10.1002/ijc.21608

16331607


48.
Mikhail
M

Velazquez
E

Shapiro
R

Berman
R

Pavlick
A

Sorhaindo
L

Spira
J

Mir
C

Panageas
KS

Polsky
D



PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation
Clin Cancer Res
2005
11
5153
5157
10.1158/1078-0432.CCR-05-0397

16033830


49.
Moore
BW


A soluble protein characteristic of the nervous system
Biochem Biophys Res Commun
1965
19
739
744
10.1016/0006-291X(65)90320-7

4953930


50.
Mouawad
R

Benhammouda
A

Rixe
O

Antoine
EC

Borel
C

Weil
M

Khayat
D

Soubrane
C


Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden
Clin Cancer Res
1996
2
1405
1409

9816314


51.
Nemunaitis
J

Fong
T

Shabe
P

Martineau
D

Ando
D


Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma
Cancer Invest
2001
19
239
247
10.1081/CNV-100102550

11338880


52.
Niezabitowski
A

Czajecki
K

Rys
J

Kruczak
A

Gruchala
A

Wasilewska
A

Lackowska
B

Sokolowski
A

Szklarski
W


Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study
J Surg Oncol
1999
70
150
160
10.1002/(SICI)1096-9098(199903)70:3<150::AID-JSO2>3.0.CO;2-Z

10102344


53.
Nikkola
J

Vihinen
P

Vuoristo
MS

Kellokumpu-Lehtinen
P

Kahari
VM

Pyrhonen
S


High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma
Clin Cancer Res
2005
11
5158
5166
10.1158/1078-0432.CCR-04-2478

16033831


54.
Nishizawa
A

Nakanishi
Y

Yoshimura
K

Sasajima
Y

Yamazaki
N

Yamamoto
A

Hanada
K

Kanai
Y

Hirohashi
S


Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients
Cancer
2005
103
1693
1700
10.1002/cncr.20984

15751018


55.
Niu
Y

Liu
F

Zhou
Z

Wang
H


Expression of CD44V6 and PCNA in squamous cell carcinomas
Chin Med J (Engl)
2002
115
1564
1568

12490112


56.
Osella-Abate
S

Quaglino
P

Savoia
P

Leporati
C

Comessatti
A

Bernengo
MG


VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course
Melanoma Res
2002
12
325
334
10.1097/00008390-200208000-00004

12170181


57.
Ostmeier
H

Fuchs
B

Otto
F

Mawick
R

Lippold
A

Krieg
V

Suter
L


Prognostic immunohistochemical markers of primary human melanomas
Br J Dermatol
2001
145
203
209
10.1046/j.1365-2133.2001.04335.x

11531780


58.
Ottaiano
A

Leonardi
E

Simeone
E

Ascierto
PA

Scala
S

Calemma
R

Bryce
J

Caraco
C

Satriano
RA

Gianfranco
N



Soluble interleukin-2 receptor in stage I-III melanoma
Cytokine
2006
33
150
155
10.1016/j.cyto.2006.01.002

16517174


59.
Persson
L

Hardemark
HG

Gustafsson
J

Rundstrom
G

Mendel-Hartvig
I

Esscher
T

Pahlman
S


S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system
Stroke
1987
18
911
918

3629651


60.
Petter
G

Haustein
UF


Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma
Dermatol Surg
2000
26
521
530
10.1046/j.1524-4725.2000.99181.x

10848931


61.
Polsky
D

Melzer
K

Hazan
C

Panageas
KS

Busam
K

Drobnjak
M

Kamino
H

Spira
JG

Kopf
AW

Houghton
A



HDM2 protein overexpression and prognosis in primary malignant melanoma
J Natl Cancer Inst
2002
94
1803
1806

12464652


62.
Rebmann
V

Ugurel
S

Tilgen
W

Reinhold
U

Grosse-Wilde
H


Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients
Int J Cancer
2002
100
580
585
10.1002/ijc.10524

12124808


63.
Redondo
P

Lloret
P

Idoate
M

Inoges
S


Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression
Clin Exp Dermatol
2005
30
541
545
10.1111/j.1365-2230.2005.01849.x

16045689


64.
Rodriguez-Rodriguez
L

Sancho-Torres
I

Gibbon
DG

Watelet
LF

Mesonero
C


CD44–9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva
J Soc Gynecol Investig
2000
7
70
75
10.1016/S1071-5576(99)00045-3

10732319


65.
Roesch
A

Becker
B

Meyer
S

Wild
P

Hafner
C

Landthaler
M

Vogt
T


Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas
Mod Pathol
2005
18
1249
1257
10.1038/modpathol.3800413

15803180


66.
Saalbach
A

Wetzel
A

Haustein
UF

Sticherling
M

Simon
JC

Anderegg
U


Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium
Oncogene
2005
24
4710
4720
10.1038/sj.onc.1208559

15897908


67.
Scala
S

Ottaiano
A

Ascierto
PA

Cavalli
M

Simeone
E

Giuliano
P

Napolitano
M

Franco
R

Botti
G

Castello
G


Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma
Clin Cancer Res
2005
11
1835
1841
10.1158/1078-0432.CCR-04-1887

15756007


68.
Scheibenbogen
C

Mohler
T

Haefele
J

Hunstein
W

Keilholz
U


Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load
Melanoma Res
1995
5
179
181

7640519


69.
Schmidt
H

Johansen
JS

Gehl
J

Geertsen
PF

Fode
K

Maase
H


Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma
Cancer
2006a
106
1130
1139
10.1002/cncr.21678

16456816


70.
Schmidt
H

Johansen
JS

Sjoegren
P

Christensen
IJ

Sorensen
BS

Fode
K

Larsen
J

Maase
H


Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma
J Clin Oncol
2006b
24
798
804
10.1200/JCO.2005.03.7960

16391295


71.
Schultz
ES

Diepgen
TL

Driesch
P


Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma
Br J Dermatol
1998
138
426
430
10.1046/j.1365-2133.1998.02119.x

9580794


72.
Sirott
MN

Bajorin
DF

Wong
GY

Tao
Y

Chapman
PB

Templeton
MA

Houghton
AN


Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis
Cancer
1993
72
3091
3098
10.1002/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V

8221576


73.
Soubrane
C

Rixe
O

Meric
JB

Khayat
D

Mouawad
R


Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study
Melanoma Res
2005
15
199
204
10.1097/00008390-200506000-00009

15917702


74.
Stahlecker
J

Gauger
A

Bosserhoff
A

Buettner
R

Ring
J

Hein
R


MIA as a reliable tumor marker in the serum of patients with malignant melanoma
Anticancer Res
2000
20
5041
5044

11326664


75.
Stoitchkov
K

Letellier
S

Garnier
JP

Bousquet
B

Tsankov
N

Morel
P

Ghanem
G

Le Bricon
T


Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker
Melanoma Res
2003
13
587
593
10.1097/00008390-200312000-00008

14646622


76.
Suiqing
C

Min
Z

Lirong
C


Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma
J Dermatol
2005
32
354
360

16043897


77.
Swart
GW

Lunter
PC

Kilsdonk
JW

Kempen
LC


Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?
Cancer Metastasis Rev
2005
24
223
236
10.1007/s10555-005-1573-0

15986133


78.
Tas
F

Duranyildiz
D

Argon
A

Oguz
H

Camlica
H

Yasasever
V

Topuz
E


Serum bcl-2 and survivin levels in melanoma
Melanoma Res
2004
14
543
546
10.1097/00008390-200412000-00017

15577328


79.
Thies
A

Moll
I

Berger
J

Wagener
C

Brummer
J

Schulze
HJ

Brunner
G

Schumacher
U


CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease
J Clin Oncol
2002
20
2530
2536
10.1200/JCO.2002.05.033

12011132


80.
Udart
M

Utikal
J

Krahn
GM

Peter
RU


Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases
Neoplasia
2001
3
245
254
10.1038/sj.neo.7900156

11494118


81.
Ugurel
S

Bell
N

Sucker
A

Zimpfer
A

Rittgen
W

Schadendorf
D


Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma
Int J Cancer
2005a
117
825
830
10.1002/ijc.21073

15957165


82.
Ugurel
S

Hildenbrand
R

Zimpfer
A

La Rosee
P

Paschka
P

Sucker
A

Keikavoussi
P

Becker
JC

Rittgen
W

Hochhaus
A



Lack of clinical efficacy of imatinib in metastatic melanoma
Br J Cancer
2005b
92
1398
1405
10.1038/sj.bjc.6602529

15846297


83.
Ugurel
S

Rappl
G

Tilgen
W

Reinhold
U


Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
J Clin Oncol
2001a
19
577
583

11208853


84.
Ugurel
S

Rappl
G

Tilgen
W

Reinhold
U


Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients
Clin Cancer Res
2001b
7
1282
1286

11350895


85.
Vergilis
IJ

Szarek
M

Ferrone
S

Reynolds
SR


Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma
J Invest Dermatol
2005
125
526
531
10.1111/j.0022-202X.2005.23798.x

16117794


86.
Vonderheid
EC

Zhang
Q

Lessin
SR

Polansky
M

Abrams
JT

Bigler
RD

Wasik
MA


Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma
J Am Acad Dermatol
1998
38
207
220
10.1016/S0190-9622(98)70597-3

9486676


87.
Vuoristo
MS

Laine
S

Huhtala
H

Parvinen
LM

Hahka-Kemppinen
M

Korpela
M

Kumpulainen
E

Kellokumpu-Lehtinen
P


Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma
Eur J Cancer
2001
37
1629
1634
10.1016/S0959-8049(01)00192-7

11527688


88.
Weinlich
G

Eisendle
K

Hassler
E

Baltaci
M

Fritsch
PO

Zelger
B


Metallothionein—overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients
Br J Cancer
2006
94
835
841
10.1038/sj.bjc.6603028

16508630


89.
Westhoff
U

Fox
C

Otto
FJ


Soluble HLA class I antigens in plasma of patients with malignant melanoma
Anticancer Res
1998
18
3789
3792

9854497


90.
Willemze
R

Jaffe
ES

Burg
G

Cerroni
L

Berti
E

Swerdlow
SH

Ralfkiaer
E

Chimenti
S

Diaz-Perez
JL

Duncan
LM



WHO-EORTC classification for cutaneous lymphomas
Blood
2005
105
3768
3785
10.1182/blood-2004-09-3502

15692063


91.
Wimmer
I

Meyer
JC

Seifert
B

Dummer
R

Flace
A

Burg
G


Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy
Cancer Res
1997
57
5073
5076

9371505


92.
Winnepenninckx
V

Lazar
V

Michiels
S

Dessen
P

Stas
M

Alonso
SR

Avril
MF

Ortiz Romero
PL

Robert
T

Balacescu
O



Gene expression profiling of primary cutaneous melanoma and clinical outcome
J Natl Cancer Inst
2006
98
472
482

16595783


93.
Wu
H

Barusevicius
A

Babb
J

Klein-Szanto
A

Godwin
A

Elenitsas
R

Gelfand
JM

Lessin
S

Seykora
JT


Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential
J Cutan Pathol
2005
32
125
130
10.1111/j.0303-6987.2005.00282.x

15606670


94.
Yamada
M

Yanaba
K

Takehara
K

Sato
S


Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma
Arch Dermatol Res
2005
297
256
260
10.1007/s00403-005-0605-5

16222535





